Unlike pan‐PI3K inhibitors, taselisib is believed to have fewer side effects and greater efficacy in treating PIK3CA‐mutant cancers, owing to its selective action on these specific PI3K isoforms [348]. The gene discussed is PIK3CA; the disease is cancer.